1. Scrip

Enanta’s Path Forward Uncertain After RSV Failure

Despite High-Risk Studies To Come

 
• By Ayisha Sharma

The US biotech’s RSV treatment candidate has failed a Phase II study in low-risk patients leaving some experts skeptical of its hopes for potential improved performance in a high-risk setting.  

RSV Is A Major Cause Of Respiratory Illness Among Young Children • Source: Shutterstock

Enanta Pharmaceuticals, Inc.’s EDP-938 has failed a mid-stage trial in respiratory syncytial virus (RSV) and while the firm was upbeat about a path forward in high-risk patients, some experts remain unconvinced.

EDP-938 missed several endpoints in the Phase IIb RSVP study but Enanta plans to continue development of the drug in a different subset of RSV patients. The placebo-controlled trial studied...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D